Received May 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4N222 | IM |
received second dose of Priorix intramuscularly instead of subcutaneous; Adult patient received Priorix vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a adult patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On 28-APR-2025, the patient received the 2nd dose of Priorix (intramuscular). On 28-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: received second dose of Priorix intramuscularly instead of subcutaneous) and inappropriate age at vaccine administration (Verbatim: Adult patient received Priorix vaccine). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-APR-2025 The pharmacist reported that an adult patient received second dose of Priorix intramuscularly instead of subcutaneous, which led to subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration